Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-09-19 00:00:00 ET · period of report 2023-09-15 · accession 0001209191-23-050030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-19 | 2023-09-15 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 881.3K | +1% | $0 |
| D | 2023-09-19 | 2023-09-15 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 871.3K | -1% | $0 |
| D | 2023-09-19 | 2023-09-15 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -10.0K | 6.51M | -0.2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-09-15 | C | A | 10,000 | $0.00 | 881,291 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-09-15 | G | D | 10,000 | $0.00 | 871,291 | D | — | — | |
| 3 | Derivative | Class B Common Stock | 2023-09-15 | C | D | 10,000 | $0.00 | 6,511,496 | D | $0.00 · — to — | 10,000 Class A Common Stock | (F6) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |